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Introduction
18F-fluorodeoxyglucose (FDG) positron emission tomography/
computer tomography (PET/CT) is an established imaging
modality in detection of a variety of malignancies and infec-
tious diseases [1–3]. From time to time, imaging shows inci-
dental sites of pathological uptake that may represent malig-
nant or premalignant lesions. Incidental findings have been de-
scribed in a number of organs, e. g. the adrenal glands (malig-
nancy rate 20%) and the thyroid (malignancy rate 50%) [4–6].
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ABSTRACT
Background and study aims Further diagnostics of inci-
dental colorectal lesions on 18F-fluorodeoxyglucose (FDG)
positron emission tomography/computed tomography
(PET/CT) is questionable. Therefore, we aimed to evaluate
the clinical importance of incidentally detected colorectal
lesions on FDG-PET/CT.
Patients and methods In the North Denmark Region, a
retrospective study was performed among 19,987 patients
who had an FDG-PET/CT from January 2006 to December
2015. Among these patients, we identified patients with a
colonoscopy within 12 months from the PET/CT scan and a
description of incidental colorectal PET-avid lesions on the
PET/CT. PET findings were compared with colonoscopy-de-
tected lesions and eventually histopathology.
Results Incidental PET-avid lesions were observed in 549
patients. Colonoscopy revealed lesions in 457 (83%),
among whom 338 patients had a final histopathological di-
agnosis. Malignant and premalignant lesions were found in
297 patients (54% among patients with a PET-avid lesion).
The lesions were cancer in 76 patients and adenoma in 221
patients of whom 30 had high-grade and 191 low-grade
adenomas. The findings changed patient management in
166 cases (30% of all patients with a PET-avid lesion). A
colonoscopy-based surveillance program was initiated for
80% of patients with high-grade adenoma. No patients
with PET-avid lesions but normal colonoscopy developed
colorectal cancer during 3 years of observation (median ob-
servation time 7 years).
Conclusions Incidental colorectal FDG uptake was infre-
quently observed, but when present, it was associated
with a high rate of malignant or premalignant lesions. Our
results indicate that patients with incidental colorectal
FDG uptake should be referred to diagnostic work-up in-
cluding colonoscopy.
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This indicates that malignancy rates of incidental FDG-PET/CT
lesions may vary among organs. Incidental uptake on FDG-
PET/CT in the colon or rectum has been described in several
studies [7]. Focal colorectal FDG uptake can indicate a variety
of lesions, both benign and malignant. The risk of malignant
and premalignant lesions reported ranges from 16% to 100%.
In some cases, the nature of the FDG uptake is unclear [8, 9].
To reveal the nature of the incidental PET-avid lesions, further
diagnostic work-up is needed. In the colon or rectum, this pri-
marily includes colonoscopy with biopsy and histopathologic
assessment [10, 11].
Previous studies included a limited number of patients. In a
systematic review of 26 studies, the median number of includ-
ed patients was 35. Only four studies included >100 patients,
one with a maximum of 239 patients [7]. Only a few studies
performed diagnostic work-up of patients with incidental colo-
rectal FDG uptake but negative colonoscopy, or performed sys-
tematic colonoscopy in all the included patients with incidental
FDG uptake [9]. Some studies stated that incidental colorectal
FDG uptake can be nonspecific and that physiological FDG up-
take is often observed in the colon and rectum [12–14]. Other
studies reported a strong correlation between incidental colo-
rectal FDG uptake and the lesion observed during colonoscopy
[15–18]. Yet no management algorithm exists to suggest the
optimal management of patients with incidental colorectal
PET-avid lesions, and the decision whether to perform further
diagnostic evaluation can be difficult [7].
To the best of our knowledge, we present data from the lar-
gest study of patients with incidental colorectal FDG-PET-avid
lesions. All followed up by colonoscopy per institutional prac-
tice and year-long follow-up for patients with negative colonos-
copy to evaluate the clinical importance of incidental colorectal
PET-avid lesions.
Patients and methods
Patients
We reviewed files from all patients undergoing an FDG-PET/CT
scan from January 2006 to December 2015at Aalborg Universi-
ty Hospital, Denmark and who subsequently had colonoscopy
within 12 months. Patients were identified by an electronic
search of the procedure codes for FDG-PET/CT and colonosco-
py. This hospital is the only site with PET/CT in the North Den-
mark Region, which has a population of approximately 600,000
inhabitants. The PET/CT scan reports of potentially eligible pa-
tients were reviewed by one person (SJK) for details on inciden-
tal findings in the colon or rectum. Any reporting of focal inci-
dental uptakes in the conclusion or description of the PET/CT
scan was included. Lesions finally characterized as physiological
diffuse uptake by the nuclear medicine physicians were not re-
garded as incidental findings. Exclusion criteria were a present
or prior history of colorectal cancer or inflammatory bowel dis-
ease.
PET/CT scan
The PET/CT was acquired on a VCT discovery True 64 PET/CT
(GE Healthcare, Chicago, Illinois, USA) in accordance with insti-
tutional procedures (370MBq of FDG, scan at 60 minutes,
blood glucose of 11mmol/L or less). The CT scan was per-
formed as low-dose CT or diagnostic, contrast-enhanced CT de-
pending on the reason for the referral and the time since the
most recent diagnostic CT had been obtained. PET images
were fused with CT and read visually and were semi-quantita-
tively assessed using a GE Advantage Workstation (GE Medical
Systems, Milwaukee, Wisconsin, USA). Per institutional prac-
tice, two independent readers trained in radiology and nuclear
medicine read the PET/CT scans and reached a conclusion in
consensus.
Colonoscopy findings
Colonoscopy was performed using a flexible endoscope per
common regional instructions at three hospitals in the North
Denmark Region. Bowel preparation was carried out according
to regional guidelines. The colonoscopy was performed by
trained endoscopists. A few patients (n =12) with an initial in-
complete colonoscopy were referred to further examination
where a sufficient colonoscopy was performed in all cases.
All colonoscopies were retrospectively reviewed through
medical records to identify colorectal lesions revealed during
colonoscopy in patients with incidental colorectal FDG uptake.
The colorectal lesions were grouped as per their appearance on
colonoscopy as likely cancer, premalignant, non-neoplastic and
benign lesions. This in accordance with the phenotypic presen-
tation of the lesions described in the colonoscopy description,
which was based on the guidelines from the Danish Colorectal
Cancer Group (DCCG). In patients with more than one lesion,
only the most severe lesion was considered in the analysis.
The medical records for patients with incidental colorectal
FDG uptake but a negative colonoscopy were reviewed to check
for later discovery of colorectal lesion. The medical records
were reviewed until May 2019.
Histopathological findings
Biopsy was performed in all patients with suspicious malignant
or premalignant lesions (n=393) on colonoscopy except from
one patient with disseminated lung cancer who had three sus-
picious colonic adenomas. The lesions judged as benign by co-
lonoscopy were, per institutional practice, not routinely biop-
sied.
Histopathological investigation of the biopsies was per-
formed using the World Health Organization histological classi-
fication of tumors of the colon and rectum (4th edition). Speci-
mens were categorized as cancer (colorectal cancer (CRC) and
non-CRC), premalignant adenomas, non-neoplastic polyps and
benign lesions. Premalignant lesions were categorized accord-
ing to the evaluation of low or high degree of neoplastic dyspla-
sia [19–21]. Benign lesions were subdivided into inflammation,
diverticulosis [22] and other less common benign lesions.
Patients with cancer of the colon or rectum or adenomas
were reviewed to check for indication for treatment [23].
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Statistical analyses
Descriptive statistics including prevalence, positive predictive
value (PPV) and sensitivity with a 95% confidence interval (95
%CI) were used.
STATA version 14 (StataCorp LP, Texas, United States) was
used for the statistical analyses; all statistical analyses were
consulted with a biostatistician at Department of Biostatistics,
Aalborg University Hospital, Denmark.
Approvals
Retrospective studies do not require ethical approval in accord-
ance with Danish national legislation. The Danish Data Protec-
tion Agency approved the study (study ID 2015–176) and
provided a waiver for informed consent regarding access to pa-
tient files.
Results
Patients
During the observation period from 2006 to 2015, an FDG-PET/
CT scan was performed in 19,987 patients of whom 1,652 pa-
tients had a colonoscopy within 1 year from the PET/CT scan
(median 22 days, range 1–350 days) (▶Fig. 1). In total, 623 pa-
tients had incidental colorectal FDG uptake. Among these pa-
tients, 74 were excluded, most frequently due to a previous
CRC. Thus, 549 patients were eligible for further analyses
(mean age 68.5 years, standard deviation (SD) 9.5, 302 males
and 247 females). The prevalence of incidental colorectal FDG
uptake leading to colonoscopy was 2.7%.
Most patients (457/549 patients, 83.2%) with incidental
colorectal FDG uptake had one or more lesions detected at co-
lonoscopy (Patient example in ▶Fig. 2). Among the 457 pa-
tients, 229 patients had one lesion and 228 had two or more le-
sions. A total of 917 lesions were found. The PPV and sensitivity
for detection of any type of lesion from incidental colorectal
FDG uptake were 83% (95%CI [80;86]) and 66% (95%CI
[62;69]), respectively. Classification of lesions by colonoscopy
is represented in ▶Table 1.
Ninety-two patients had a negative colonoscopy of whom
none were diagnosed with CRC within a median follow-up time
of 7.2 years (range 3.4–12.6 years). Thirteen patients (14.1%)
had developed benign or low-grade dysplastic lesions as evi-
denced by colonoscopy within the follow-up period (mean 4.7
years; range 1.1–9.5 years).
Histopathological findings
For the 457 patients, the colorectal lesion was assessed with a
biopsy in 338 (338/457 patients, 74.0%). A biopsy was per-
formed in all patients with a suspected cancer or a premalig-
nant lesion (n =297) on colonoscopy, except from one patient
with disseminated lung cancer who had three suspected colo-
nic adenomas. The non-neoplastic and benign lesions were
less frequently histopathologically assessed by a biopsy. A biop-
sy was taken from 26 of the 61 patients with a non-neoplastic
lesion (42.6%) and from 15 of the 98 patients with a benign le-
sion judged by colonoscopy (15.3%). A total of 338 patients had
a final histopathological diagnosis.
Among these 338 patients, 76 patients were diagnosed with
cancer, 67 patients with CRC, eight patients with non-CRC
(types of cancer: Mantel cell lymphoma, malign melanoma,
squamous cell carcinoma, neuroendocrine cancer, medullary
carcinoma, malign lymphoma), and one patient with CRC as
well as non-CRC (Mantel cell lymphoma). A total of 221 patients
were diagnosed with a biopsy-verified high- to low-grade ade-
nomas, 30 patients with high-grade adenomas and 191 pa-
tients with low-grade adenomas. The PPV and sensitivity for de-
tection of a cancer or premalignant lesion from incidental colo-
rectal FDG uptake were 72% (95% CI [68;75]) and 57% (95% CI
[53;60]), respectively; and for detection of a CRC 12% (95%CI
[10;15]) and 10% (95%CI [8;12]), respectively. A total of 41 pa-
tients had a biopsy-verified non-neoplastic or benign lesion.
The histopathological classification of the lesions is represen-
ted in ▶Table 2.
Change of patient management
The overall findings had a notable impact on patient manage-
ment, both at the time of the diagnosis and at follow-up.
Among the 76 patients with an incidental cancer in the colon/
rectum, 37 patients underwent intended curative treatment
(surgery incl. chemotherapy before surgery, radiation therapy)
Patients without 
incidental colorectal FDG 
uptake on the PET/CT 
scan: n = 1029
Patients without 
lesions observed during 
colonoscopy:
n = 92
Patients excluded due to 
(n = 74): 
▪ Prior colorectal cancer
 (n = 41)
▪ Current colorectal 
 cancer (n = 27)
▪ Colorectal inflammatory
 disease (n = 6)
Patients with a FDG-PET/CT scan:
n = 19,987
Patients with a PET/CT scan and colonoscopy 
within 12 months: n = 1,652
Patients with incidental 
colorectal FDG uptake:
n = 623
Patients eligible for 
further analysis: 
n = 549
Patients with one or 
more lesion(s) found 
during colonoscopy: 
n = 457
▶ Fig. 1 Flowchart of the inclusion and exclusion process.
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and 29 patients received palliative treatment. Ten patients had
no further treatment due to primary cancer prognosis or co-
morbidity (9 patients with CRC, 1 patient with non-CRC). In to-
tal 37 of the 76 patients had a change in patient management.
Because of the findings during colonoscopy and pathology, a
surveillance program with colonoscopy was initiated in 24 of 30
patients (80%) with high-grade dysplasia adenomas and in 105
patients of the 191 patients (55%) with low-grade dysplasia
adenomas.
Discussion
To the best of our knowledge, this study is the largest study of
patients with incidental colorectal FDG-PET-avid lesions fol-
lowed by colonoscopy per institutional practice and year-long
follow-up for patients with negative colonoscopy. Pathology
showed cancer or premalignant lesions in nearly 300 of 549 pa-
tients with PET-avid colonic accidental findings, including 67
patients with CRC and 30 patients with high-grade adenoma.
In the majority of the patients, patient management was chan-
ged because of the pathology findings. This underlines that in-
cidental FDG-PET-avid lesions in the colon should be followed
up with colonoscopy and with histopathological assessment in
case of suspicion of malignancy.
The wide use FDG-PET/CT imaging introduced the dilemma
of incidental PET-avid lesions, which poses challenges to clini-
cians. The prevalence of incidental colorectal PET-avid lesions
is, however, relatively low. In a review, studies from 2002 to
2012 [9], reported detection rates of incidental colorectal PET-
avid lesions within a range of 0.4% to 16.3%. A meta-analysis by
Treglia et al. reported a pooled prevalence of 3.6% [9]. In the
present study, we observed colorectal PET-avid lesions leading
to colonoscopy among 2.7% of the patients undergoing FDG-
PET/CT for various reasons. The risk of incidental PET-avid le-
sions turning into malignant lesions is often the reason for re-
ferral to further diagnostic work-up. Risk of malignant and pre-
malignant lesions was reported in the literature with a range of
16% to 100% of the cases. A meta-analysis based on 23 eastern
and western studies described a pooled risk of malignant and
premalignant lesions of 68% [9]. In the present study, we found
a risk of malignant lesions of 12% and of premalignant lesions
(adenomas) of 72%. This illustrates a strong correlation be-
▶ Fig. 2 An 86-year-old women had an 18F-fluorodeoxyglucose positron emission tomography/computer tomography (FDG-PET/CT) scan be-
cause of a gynecological cancer. There was incidental FDG uptake in the sigmoid colon. The patient underwent colonoscopy-assisted biopsy,
which showed colorectal cancer. a The CT image showing a colorectal lesion with an arrow indicating the site of most intense FDG uptake on
the fused image. b The PET image. c Fused PET/CT image showing FDG uptake (standardized uptake value, SUV 18.5) in the recto sigmoid
transition (white arrow). d Colonoscopy image showed the colorectal lesion.
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tween incidental colorectal abnormalities detected on FDG-
PET/CT images and colorectal lesions confirmed at histopatho-
logical assessment, where malignant and premalignant lesions
often are diagnosed.
No published international management algorithm exists to
inform management of patients with incidental colorectal FDG
uptake. At our institution, all patients with incidental colorectal
PET-avid lesions are automatically referred to colonoscopy. The
findings of our study support that whenever a focal hot spot is
detected within the large bowel or rectum, further diagnostic
work-up such as colonoscopy and histopathological assessment
should be performed to exclude malignant or premalignant le-
sions. Contingent on this is, however, that patients are deemed
fit for further diagnostic work-up or have a reasonable prog-
nosis for the lesions [24]. Salazar Andia and colleagues showed
that PET/CT modified the diagnostic and treatment manage-
ment in approximately 90% of the patients undergoing colo-
noscopy for PET-avid lesions [17]; and Valente MA showed
change in treatment of 85% of patients with a diagnosed CRC
[25]. This is somewhat in line with our findings. We observed a
change in patient management for 37 of the 76 patients (49%)
diagnosed with a cancer in the colon or the rectum. A surveil-
lance program with colonoscopy was established for 80% of
the patients with high-grade adenoma and 55% of the patients
with low-adenoma.
Most studies on FDG-avid colon lesions include a limited
number of patients [7]. This study is the largest study of its
kind with more than twice the number of the patients reported
previously [26]. All the included patients with incidental colo-
rectal FDG uptake described on the PET/CT scan were referred
to colonoscopy with later histopathological assessment of the
lesion in 74% of the patients; such a systematic approach has
not been conducted in previous studies [9]. Only four studies
described a follow-up colonoscopy in patients with incidental
colorectal FDG uptake but no lesions were discovered during
the diagnostic colonoscopy [8, 27–29]. None of these four
studies observed colorectal lesions at the follow-up colonosco-
py. In our study, we observed no cases of colorectal cancer or
high-grade adenoma at a follow-up colonoscopy after at least
3 years in patients with FDG uptake but negative diagnostic co-
lonoscopy.
The study design of the present study was that of a historical
cohort study, and the data was collected from the different reg-
isters at the university hospital. Even though it was institutional
practice to perform colonoscopy in the case of FDG-avid colo-
nic lesions, it can be hypothesized that for various reasons
some patients did not receive a colonoscopy. The true epide-
miology and malignancy rates of FDG-avid lesions should likely
be examined in a prospective cohort. Colonoscopy revealed le-
sions in most, but not all patients with FDG-avid lesions. The
true nature of the PET-avid lesions in patients with a negative
colonoscopy remains unknown. However, none of nearly hun-
▶Table 1 Clinical characterization of lesions by colonoscopy in pa-
tients with incidental colorectal FDG uptake (n =549).
Population Colonoscopy
Malignant lesion
▪ Cancer, n (%)  76 (13.8%)
Premalignant lesion
▪ Adenoma, n (%) 222 (40.4%)
Non-neoplastic lesion
▪ Hyperplastic polyp, n (%)  22 (4.0%)
▪ Sessile serrate polyp, n (%)   5 (0.9%)
▪ Unclassified polyp, n (%)  34 (6.2%)
Benign lesion
▪ Diverticulosis, n (%)  82 (14.9%)
▪ Acute or chronic inflammation, n (%)   9 (1.6%)
▪ Others (e. g. chronic inflammatory bowel
disease), n (%)
  7 (1.3%)
No lesions detected
▪ n (%)  92 (16.8%)
▶Table 2 Final histopathological diagnosis of the biopsy-verified le-
sions discovered during colonoscopy in patients with incidental colo-
rectal FDG uptake (n =338).
Population Histo-
pathology
Malignant lesion (cancer)
▪ CRC adenocarcinoma, n (%)  67 (19.8%)
▪ Non-CRC, n (%)   8 (2.4%)
▪ CRC and non-CRC, n (%)   1 (0.3%)
Premalignant lesion (adenoma)
▪ High-grade adenoma, tubular adenoma, n (%)  21 (6.2%)
▪ High-grade adenoma, tubulovillous adenoma,
n (%)
  6 (1.8%)
▪ High-grade adenoma, villous adenoma, n (%)   3 (0.9%)
▪ Low-grade adenoma, tubular adenoma, n (%) 176 (52.1%)
▪ Low-grade adenoma, tubulovillous adenoma,
n (%)
  7 (2.1%)
▪ Low-grade adenoma, serrate adenoma, n (%)   5 (1.5%)
▪ Low-grade adenoma, villous adenoma, n (%)   3 (0.9%)
Non-neoplastic lesion
▪ Hyperplastic polyp, n (%)  21 (6.2%)
▪ Sessile serrate polyp, n (%)   5 (1.5%)
Benign lesion
▪ Acute or chronic inflammation, n (%)   8 (2.4%)
▪ Others (e. g. chronic inflammatory bowel
disease), n (%)
  7 (2.1%)
CRC, colorectal cancer.
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dred patients without colonoscopic findings developed colo-
rectal cancer during an observation period at least 3.4 years, in-
dicating that colonoscopy was sufficient as an investigative
modality of FDG-avid lesions. Biopsy was not sampled for all le-
sions, especially not for apparently benign lesions detected
during the colonoscopy. This practice was not unique for our
study; such practice was described in other studies as well
[17]. However, it is a limitation of our study.
Several patients presented with more than one lesion during
colonoscopy. Every attempt was made to explore findings at
the PET with the localization at colonoscopy, which is also de-
scribed in the literature [30]. We did not explore the association
of the anatomical location of the PET-avid lesions with individ-
ual findings on colonoscopy and the final pathological refer-
ence. Here, we focused on the clinical impact of PET-avid inci-
dental findings on the final outcome at the patient level. A sep-
arate paper is in preparation for lesion analysis.
Conclusion
Our study demonstrated that incidental colorectal FDG uptake
was infrequently observed. However, when present, it was
associated with a high risk of cancer and/or high-grade adeno-
mas leading to change of patient management. It is recom-
mend that patients with incidental colorectal FDG uptake be re-
ferred to colonoscopy in all cases where the patient is consid-
ered suitable for further treatment. We encourage societies to
issue recommendations for handling of FDG-avid colonic le-
sions.
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